GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipocine Inc (NAS:LPCN) » Definitions » Cyclically Adjusted Price-to-FCF

LPCN (Lipocine) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Lipocine Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lipocine Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Lipocine's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipocine Cyclically Adjusted Price-to-FCF Chart

Lipocine Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.14 - - -

Lipocine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lipocine's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Lipocine's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipocine's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipocine's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lipocine's Cyclically Adjusted Price-to-FCF falls into.


;
;

Lipocine Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Lipocine's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Lipocine's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.368/134.9266*134.9266
=-0.368

Current CPI (Mar. 2025) = 134.9266.

Lipocine Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -3.984 100.684 -5.339
201509 -5.193 100.392 -6.979
201512 -2.714 99.792 -3.670
201603 -6.097 100.470 -8.188
201606 -4.838 101.688 -6.419
201609 -3.771 101.861 -4.995
201612 -2.369 101.863 -3.138
201703 -2.851 102.862 -3.740
201706 -4.124 103.349 -5.384
201709 -3.715 104.136 -4.813
201712 -3.443 104.011 -4.466
201803 -2.994 105.290 -3.837
201806 -2.190 106.317 -2.779
201809 -2.686 106.507 -3.403
201812 -1.757 105.998 -2.237
201903 -2.184 107.251 -2.748
201906 -1.768 108.070 -2.207
201909 -1.909 108.329 -2.378
201912 -1.836 108.420 -2.285
202003 -1.388 108.902 -1.720
202006 -1.393 108.767 -1.728
202009 -1.092 109.815 -1.342
202012 -0.940 109.897 -1.154
202103 -0.843 111.754 -1.018
202106 -0.451 114.631 -0.531
202109 -1.334 115.734 -1.555
202112 1.720 117.630 1.973
202203 -0.753 121.301 -0.838
202206 -0.581 125.017 -0.627
202209 -0.609 125.227 -0.656
202212 -0.369 125.222 -0.398
202303 -0.751 127.348 -0.796
202306 -0.632 128.729 -0.662
202309 -0.492 129.860 -0.511
202312 -0.380 129.419 -0.396
202403 0.449 131.776 0.460
202406 -0.467 132.554 -0.475
202409 -0.530 133.029 -0.538
202412 0.299 133.157 0.303
202503 -0.368 134.927 -0.368

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lipocine  (NAS:LPCN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Lipocine Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Lipocine's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipocine Business Description

Industry
Traded in Other Exchanges
N/A
Address
675 Arapeen Drive, Suite 202, Salt Lake City, UT, USA, 84108
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Executives
Mahesh V. Patel director, officer: President and CEO C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Richard Dana Ono director 18 SPRING ROAD, CONCORD MA 01742
Spyridon Papapetropoulos director C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
George Nomikos officer: Chief Medical Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Krista Fogarty officer: Principal Accounting Officer 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY UT 84108
Jill M. Jene director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
John W. Higuchi director C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Morgan R Brown officer: EVP and CFO 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Jeffrey Arvin Fink director 2265 MORNING STAR DRIVE, PARK CITY UT 84060
Gregory Brooks Bass officer: EVP and Chief Commercial Offic 3228 BROOKSIDE DRIVE, FURLONG PA 18925
Jyrki Mattila officer: Chief Business Officer AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Srinivasan Venkateshwaran officer: CTO and VP RandD C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Robert K. Merrell officer: VP Finance C/O LIPOCINE, INC., 675 ARAPEEN DRIVE, STE. 202, SALT LAKE CITY UT 84108
Gerald T Simmons officer: VP Corp Business Development 837 4TH AVE, SALT LAKE CITY UT 84103